Inspire Investing LLC Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Inspire Investing LLC reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 66.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,479 shares of the biotechnology company’s stock after selling 104,529 shares during the quarter. Inspire Investing LLC’s holdings in BioCryst Pharmaceuticals were worth $402,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. American Century Companies Inc. lifted its position in shares of BioCryst Pharmaceuticals by 896.6% during the second quarter. American Century Companies Inc. now owns 148,490 shares of the biotechnology company’s stock worth $918,000 after acquiring an additional 133,591 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in BioCryst Pharmaceuticals by 32.7% during the 2nd quarter. Hsbc Holdings PLC now owns 125,004 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 30,788 shares in the last quarter. Xponance Inc. lifted its holdings in BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,505 shares in the last quarter. AQR Capital Management LLC boosted its stake in BioCryst Pharmaceuticals by 18.8% in the 2nd quarter. AQR Capital Management LLC now owns 543,241 shares of the biotechnology company’s stock worth $3,357,000 after purchasing an additional 85,871 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in BioCryst Pharmaceuticals by 113.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 212,581 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 113,152 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.64 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The firm’s fifty day moving average price is $7.57 and its 200-day moving average price is $7.66. The stock has a market cap of $1.58 billion, a P/E ratio of -12.52 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period last year, the firm earned ($0.19) EPS. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of recent analyst reports. Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC boosted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.